Por: Associated Press Business December 12, 2022
Amgen is spending more than $26 billion to dive deeper into rare disease treatments with a deal for drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that generated more than $1 billion in its first full year on the market. The deal offers Amgen another chance to build its portfolio of rare-disease treatments after it... + full article
CNBC USA Business December 12, 2022
Check out the companies making headlines in midday trading. – Shares of the drugmaker jumped 15% after the company announced it by Amgen in a deal valued at approximately $26.4 billion, or $116.50 per share, in cash. The deal will give Amgen a chance to build its portfolio... + más
Port St. Lucie child shot when father, under influence of alcohol, 'irresponsibly handled' AR-15, police say | WPTV
Thoma Bravo to take Coupa Software private in $8B deal | Fox Business
Forbes USA Business December 12, 2022
Hedge fund billionaire John Paulson stands to make a half billion dollars from Horizon's sale to Amgen.Patrick McMullan via Getty Images It’s not , but for hedge fund billionaire John Paulson, it wasn’t so bad either. Paulson’s firm, Paulson & Co., famously made... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | Associated Press
Thorns owner Paulson steps away after damning abuse report | WPLG Local 10
Fox Business USA Business December 12, 2022
Graviton Biopharmaceutical Holdings Chairman and CEO Sam Waksal discusses growth investment opportunities in biotech and how the sector should be a national priority. Amgen announced on Monday that it will acquire Horizon Therapeutics in a $26 billion deal, extending the... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | 10 WBNS
ABC News USA Health December 12, 2022
Amgen is spending more than $26 billion to dive deeper into rare disease treatments with the acquisition of drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a treatment for thyroid eye... + más
10 WBNS USA Health December 12, 2022
LOS ANGELES — Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, for about $26.4 billion. Each Horizon shareholder will receive $116.50 per share for each share they own. The deal has an enterprise... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | ABC News
Los Angeles Times USA Science December 12, 2022
9to5Mac USA Tech October 07, 2022
It seems is having problems persuading even its own employees to don one of its headsets and use its primary metaverse app, Horizon Worlds. So much so that an internal memo says the company would “hold managers accountable” for their teams using it. It’s one of a set of... + más
Meta’s VR social network Horizon is too buggy and employees are barely using it | The Verge
When metaverse worlds collide in Congress | The Hill
About iurex | Privacy Policy | Disclaimer |